Related Experiment Video
Updated: Aug 27, 2025

Assessing Whole-Body Lipid-Handling Capacity in Mice
Published on: November 24, 2020
[A practitioner's perspective of the latest lipid guidelines]
Loic Ponet1, Livio Franchetti1, Kevin Dobretz2
1Service de médecine de premier recours, Département de médecine de premiers recours, Hôpitaux universitaires de Genève, 1211 Genève 14.
The latest European Society of Cardiology (ESC) guidelines introduce new cardiovascular risk stratification. New targets for low-density lipoprotein cholesterol (LDL-C) are proposed for apparently healthy individuals and those with specific risks.
Area of Science:
- Cardiology
- Preventive Medicine
- Clinical Practice Guidelines
Background:
- The European Society of Cardiology (ESC) periodically updates cardiovascular disease (CVD) prevention guidelines.
- Previous guidelines focused on general risk assessment, but recent evidence highlights the need for tailored approaches based on specific patient profiles.
Purpose of the Study:
- To summarize the key updates and new concepts introduced in the latest ESC recommendations for cardiovascular risk management.
- To highlight the revised approach to stratifying patients and setting lipid-lowering targets.
Main Methods:
- Review of the latest published ESC guidelines on cardiovascular disease prevention.
- Analysis of the proposed new risk calculation tools (SCORE2 and SCORE2-OP).
- Examination of the differentiated low-density lipoprotein cholesterol (LDL-C) targets based on patient risk categories.
Main Results:
- The guidelines differentiate between apparently healthy individuals and those with specific cardiovascular risks (e.g., diabetes, renal failure, familial hypercholesterolemia).
- New risk assessment tools, SCORE2 and SCORE2-OP, are introduced.
- Specific LDL-C targets are proposed: generally < 1.8 mmol/l for high-risk and < 1.4 mmol/l for very-high-risk individuals.
- Therapeutic strategies incorporate risk modifiers, comorbidities, and patient preferences, emphasizing lifestyle optimization and statin therapy.
Conclusions:
- The updated ESC recommendations offer a more personalized approach to cardiovascular risk management.
- Clinicians should utilize the new risk scores and tailored LDL-C targets for effective patient care.
- Integrating patient-specific factors is crucial for optimizing lifestyle and pharmacological interventions.
Related Concept Videos
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipids: Dietary Sources and Requirements
Atherosclerosis III: Management
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Lipid-derived Compounds in the Human Body
Fat-soluble Vitamins
Fat-soluble vitamins, including vitamins A, D, E, and K, are required in minimal quantities, but their deficiencies can lead to severely abnormal physiological conditions. For example, vitamin A deficiency can cause night blindness, dry skin,...

